KCC009是一种高特异性、不可逆的transglutaminase 2 (TG2)抑制剂，可诱导不依赖于p53的放射增敏作用。
Cas No.:744198-19-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
KCC009, a highly specific and irreversible inhibitor of transglutaminase 2 (TG2), can induce p53-independent radio-sensitization[1]. KCC009 can disrupt the adhesion plaque complex on the surface of glioblastoma cells, resulting in a decrease in cell migration ability, making the cells more sensitive to chemotherapy and leading to cell death[2]. KCC009 has been widely used to promote apoptosis of glioma and meningioma cells, and to enhance the chemosensitivity of cells[3].
In vitro, KCC009 pretreatment (250μM) for 1 hour can inhibit the production of cytokines in UV-irradiated keratinocytes and reduce the transcriptional activity of NF-κB[4]. Pretreatment of KCC009 (3.91μM; 24 hours) increased the expression of p21, Bax, p-caspase-3, and decreased expressions of Bcl-2 and Cyclin D in irradiated (6Gy) H1299/WT-p53 cells[5]. Treatment with 1mM KCC009 for 24 hours can induce apoptosis in U87 cells, accompanied by cell detachment from the cell culture plate and loss of cell membrane integrity[6].
In vivo, KCC009 treatment via intraperitoneal injection (20mg/kg; three times a day) for 6 days can alleviate the liver hypertrophy induced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) in mice[7]. Daily intraperitoneal injection of a 50mg/kg dose of KCC009 for 6 weeks prevented the increase in total calcium extraction in the aortic tissue of rats induced by warfarin [8].
References:
[1] Frese-Schaper M, Schardt J A, Sakai T, et al. Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5[J]. FEBS letters, 2010, 584(13): 2867-2871.
[2] Yuan L, Behdad A, Holmes T, et al. Tissue transglutaminase 2 inhibitor, KCC009 results in disruption of focal adhesion complexes in glioblastoma cells with subsequent loss of cellular motility and sensitization to cell death[J]. Cancer Research, 2008, 68(9_Supplement): LB-193-LB-193.
[3] Yuan L, Behdad A, Siegel M, et al. Tissue transgluaminase 2 expression in meningiomas[J]. Journal of neuro-oncology, 2008, 90(2): 125-132.
[4] Lee S J, Lee K B, Son Y H, et al. Transglutaminase 2 mediates UV-induced skin inflammation by enhancing inflammatory cytokine production[J]. Cell death & disease, 2017, 8(10): e3148-e3148.
[5] Huayin S, Dong Y, Chihong Z, et al. Transglutaminase 2 inhibitor KCC009 induces p53-independent radiosensitization in lung adenocarcinoma cells[J]. Medical science monitor: international medical journal of experimental and clinical research, 2016, 22: 5041.
[6] Yuan L, Choi K, Khosla C, et al. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas[J]. Molecular cancer therapeutics, 2005, 4(9): 1293-1302.
[7] Strnad P, Siegel M, Toivola D M, et al. Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation[J]. FEBS letters, 2006, 580(9): 2351-2357.
[8] Beazley K E, Banyard D, Lima F, et al. Transglutaminase inhibitors attenuate vascular calcification in a preclinical model[J]. Arteriosclerosis, thrombosis, and vascular biology, 2013, 33(1): 43-51.
KCC009是一种高特异性、不可逆的transglutaminase 2 (TG2)抑制剂，可诱导不依赖于p53的放射增敏作用[1]。KCC009能够破坏胶质母细胞瘤细胞表面的粘附斑复合物，导致细胞迁移能力下降，使细胞对化疗更敏感，从而引发细胞死亡[2]。KCC009已被广泛用于促进胶质瘤和脑膜瘤细胞凋亡，并增强细胞的化疗敏感性[3]。
在体外，用250μM的KCC009预处理1小时，可抑制紫外线照射的角质形成细胞中细胞因子的产生，并降低NF-κB的转录活性[4]。用3.91μM的KCC009预处理24小时，可增加受照射（6Gy）的H1299/WT-p53细胞中p21、Bax、p-caspase-3的表达，并降低Bcl-2和Cyclin D的表达。用1mM的KCC009处理 U87细胞24小时，可诱导细胞凋亡，伴随细胞从培养板上脱落和细胞膜完整性丧失[6]。
在体内，通过腹腔注射KCC009（20mg/kg；每日三次）连续6天，可减轻3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)诱导的小鼠肝脏肥大[7]。每日腹腔注射50mg/kg剂量的KCC009，连续6周，可阻止warfarin诱导的大鼠主动脉组织中总钙增加[8]。
| Cell experiment [1]: | |
Cell lines | U87 cells |
Preparation Method | U87 cells were cultured in MEM medium supplemented with 10% fetal bovine serum (FBS), 100units/ml penicillin, 100μg/ml streptomycin, 0.1mM nonessential amino acids, 1mM sodium pyruvate, and 2mM glutamine at 37℃ in the presence of 5% CO2. After cells reached 60% confluence, groups were treated with vehicle (1% DMSO) or with 0.1, 0.5, and 1.0mM KCC009, respectively, for 24h. Analyze the rate of cell apoptosis. |
Reaction Conditions | 0.1, 0.5, and 1mM; 24h |
Applications | KCC009 treatment significantly enhanced the apoptosis of U87 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | C3H mice |
Preparation Method | C3H mice (8-week-old) were housed in temperature (23±2°C) and light-controlled (12:12-hour light-dark cycle) animal care facility. Mice were fed a powdered diet containing 0.1% DDC for 3 months. Mice were recovered for 4 weeks on a standard diet (termed “primed mice” after recovery), then divided into 3 groups (8 mice/group). One group was given KCC009 alone (20mg/kg; three times a day), and the remaining two groups were re-fed the DDC-containing diet (6 days) either alone or with KCC009 (20mg/kg; three times a day). Collect the mouse liver for analysis. |
Dosage form | 20mg/kg; three times a day for 6 days; i.p. |
Applications | KCC009 treatment alleviated the liver hypertrophy induced by DDC in mice. |
References: | |
| Cas No. | 744198-19-4 | SDF | Download SDF |
| 分子式 | C21H22BrN3O5 | 分子量 | 476.32 |
| 溶解度 | DMSO : 250 mg/mL (524.86 mM; Need ultrasonic) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0994 mL | 10.4971 mL | 20.9943 mL |
| 5 mM | 419.9 μL | 2.0994 mL | 4.1989 mL |
| 10 mM | 209.9 μL | 1.0497 mL | 2.0994 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet